Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
74,361,296
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
14,645,573
-
Shares change
-
+980,838
-
Total reported value, excl. options
-
$208,464,147
-
Value change
-
+$13,774,406
-
Number of buys
-
32
-
Number of sells
-
-16
-
Price
-
$14.26
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) as of Q2 2016
52 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock as of Q2 2016.
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14,645,573 shares
of 74,361,296 outstanding shares and own 19.7% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (5,379,349 shares), Novo A/S (3,224,046 shares), FMR LLC (2,311,297 shares), PRICE T ROWE ASSOCIATES INC /MD/ (634,888 shares), JENNISON ASSOCIATES LLC (570,481 shares), BlackRock Advisors LLC (456,117 shares), Rock Springs Capital Management LP (450,000 shares), SPHERA FUNDS MANAGEMENT LTD. (325,053 shares), Cormorant Asset Management, LLC (214,132 shares), and Alyeska Investment Group, L.P. (200,873 shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.